Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.

Warren, Hannah R; Ross, Sarah J; Smith, Paul D; Coulson, Judy M; Prior, Ian A

Warren, Hannah R; Ross, Sarah J; Smith, Paul D; Coulson, Judy M; Prior, Ian A.

Afiliación

Warren HR; Department of Molecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, U.K.
Ross SJ; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Smith PD; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Coulson JM; Department of Molecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, U.K.
Prior IA; Department of Molecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, U.K.

Biochem J ; 479(18): 1985-1997, 2022 09 30.

Article en En | MEDLINE | ID: mdl-36065754

Asunto(s)

Neoplasias Pulmonares; Proteínas Proto-Oncogénicas p21(ras); Humanos; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Mutación; Proteínas Proto-Oncogénicas p21(ras)/genética; Transducción de Señal

Palabras clave

G-proteins; drug resistance; signaling

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Biochem J Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google